156 related articles for article (PubMed ID: 35019216)
61. Midostaurin in combination with chemotherapy is most effective in patients with acute myeloid leukemia presenting with high FLT3-ITD allelic ratio who proceed to allogeneic stem cell transplantation while in first complete remission.
Ofran Y; Leiba R; Frisch A; Horesh N; Henig I; Yehudai-Ofir D; Moshe Y; Neaman M; Ganzel C; Gal-Rabinovich K; Hellmann I; Weinstein V; Berger T; Wolach O
Eur J Haematol; 2021 Jan; 106(1):64-71. PubMed ID: 32949053
[TBL] [Abstract][Full Text] [Related]
62. miR-155 promotes FLT3-ITD-induced myeloproliferative disease through inhibition of the interferon response.
Wallace JA; Kagele DA; Eiring AM; Kim CN; Hu R; Runtsch MC; Alexander M; Huffaker TB; Lee SH; Patel AB; Mosbruger TL; Voth WP; Rao DS; Miles RR; Round JL; Deininger MW; O'Connell RM
Blood; 2017 Jun; 129(23):3074-3086. PubMed ID: 28432220
[TBL] [Abstract][Full Text] [Related]
63. [Effect of FLT3-ITD with DNMT3A R882 double-mutation on the prognosis of acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation].
Tang SH; Lu Y; Zhang PS; Liu XH; Du XH; Chen D; Sha KY; Li SY; Cao JJ; Chen LG; Zhuang XX; Pei RZ; Tang XW
Zhonghua Xue Ye Xue Za Zhi; 2018 Jul; 39(7):552-557. PubMed ID: 30122013
[No Abstract] [Full Text] [Related]
64. Myeloid/Lymphoid Neoplasms with Eosinophilia and TK Fusion Genes, Version 3.2021, NCCN Clinical Practice Guidelines in Oncology.
Gerds AT; Gotlib J; Bose P; Deininger MW; Dunbar A; Elshoury A; George TI; Gojo I; Gundabolu K; Hexner E; Hobbs G; Jain T; Jamieson C; Kuykendall AT; McMahon B; Mohan SR; Oehler V; Oh S; Pardanani A; Podoltsev N; Ranheim E; Rein L; Salit R; Snyder DS; Stein BL; Talpaz M; Thota S; Vachhani P; Wadleigh M; Walsh K; Ward DC; Bergman MA; Sundar H
J Natl Compr Canc Netw; 2020 Sep; 18(9):1248-1269. PubMed ID: 32886902
[TBL] [Abstract][Full Text] [Related]
65. Lack of CD45 in FLT3-ITD mice results in a myeloproliferative phenotype, cortical porosity, and ectopic bone formation.
Kresinsky A; Schnöder TM; Jacobsen ID; Rauner M; Hofbauer LC; Ast V; König R; Hoffmann B; Svensson CM; Figge MT; Hilger I; Heidel FH; Böhmer FD; Müller JP
Oncogene; 2019 Jun; 38(24):4773-4787. PubMed ID: 30820040
[TBL] [Abstract][Full Text] [Related]
66. A novel t(3;13)(q13;q12) translocation fusing FLT3 with GOLGB1: toward myeloid/lymphoid neoplasms with eosinophilia and rearrangement of FLT3?
Troadec E; Dobbelstein S; Bertrand P; Faumont N; Trimoreau F; Touati M; Chauzeix J; Petit B; Bordessoule D; Feuillard J; Bastard C; Gachard N
Leukemia; 2017 Feb; 31(2):514-517. PubMed ID: 27795560
[No Abstract] [Full Text] [Related]
67. Impact of FLT3 internal tandem duplication on the outcome of related and unrelated hematopoietic transplantation for adult acute myeloid leukemia in first remission: a retrospective analysis.
Brunet S; Labopin M; Esteve J; Cornelissen J; Socié G; Iori AP; Verdonck LF; Volin L; Gratwohl A; Sierra J; Mohty M; Rocha V
J Clin Oncol; 2012 Mar; 30(7):735-41. PubMed ID: 22291086
[TBL] [Abstract][Full Text] [Related]
68. Allogeneic stem cell transplantation and targeted therapy for FLT3/ITD+ acute myeloid leukemia: an update.
Hu B; Vikas P; Mohty M; Savani BN
Expert Rev Hematol; 2014 Apr; 7(2):301-15. PubMed ID: 24308526
[TBL] [Abstract][Full Text] [Related]
69. NUP98-NSD1 fusion in association with FLT3-ITD mutation identifies a prognostically relevant subgroup of pediatric acute myeloid leukemia patients suitable for monitoring by real time quantitative PCR.
Akiki S; Dyer SA; Grimwade D; Ivey A; Abou-Zeid N; Borrow J; Jeffries S; Caddick J; Newell H; Begum S; Tawana K; Mason J; Velangi M; Griffiths M
Genes Chromosomes Cancer; 2013 Nov; 52(11):1053-64. PubMed ID: 23999921
[TBL] [Abstract][Full Text] [Related]
70. Constitutive activation of Flt3 and STAT5A enhances self-renewal and alters differentiation of hematopoietic stem cells.
Moore MA; Dorn DC; Schuringa JJ; Chung KY; Morrone G
Exp Hematol; 2007 Apr; 35(4 Suppl 1):105-16. PubMed ID: 17379095
[TBL] [Abstract][Full Text] [Related]
71. Whole-genome optical mapping to elucidate myeloid/lymphoid neoplasms with eosinophilia and tyrosine kinase gene fusions.
Podvin B; Roynard P; Boudry A; Guermouche H; Daudignon A; Terriou L; Bouabdelli W; Salameh M; Grardel N; Duployez N; Roche-Lestienne C
Leuk Res; 2022 Dec; 123():106972. PubMed ID: 36306722
[No Abstract] [Full Text] [Related]
72. FLT3 Internal Tandem Duplication Mutation, cMPL and CD34 Expressions Predict Low Survival in Acute Myeloid Leukemia Patients.
Ebrahim EK; Assem MM; Amin AI; Kamel MM; El Meligui YM; Metwally AM
Ann Clin Lab Sci; 2016 Dec; 46(6):592-600. PubMed ID: 27993871
[TBL] [Abstract][Full Text] [Related]
73. Allogeneic hematopoietic stem cell transplantation at the first remission for younger adults with FLT3-internal tandem duplication AML: The JALSG AML209-FLT3-SCT study.
Kawashima N; Ishikawa Y; Atsuta Y; Sawa M; Ozawa Y; Hayashi M; Kohno A; Tomita A; Maeda T; Sakaida E; Usuki K; Hagihara M; Kanamori H; Matsuoka H; Kobayashi M; Asou N; Ohtake S; Matsumura I; Miyazaki Y; Naoe T; Kiyoi H;
Cancer Sci; 2020 Jul; 111(7):2472-2481. PubMed ID: 32391628
[TBL] [Abstract][Full Text] [Related]
74. Myeloid/lymphoid neoplasms with eosinophilia and tyrosine kinase fusion genes: A workshop report with focus on novel entities and a literature review including paediatric cases.
Saft L; Kvasnicka HM; Boudova L; Gianelli U; Lazzi S; Rozman M
Histopathology; 2023 Dec; 83(6):829-849. PubMed ID: 37551450
[TBL] [Abstract][Full Text] [Related]
75. Patient-specific analysis of FLT3 internal tandem duplications for the prognostication and monitoring of acute myeloid leukemia.
Schiller J; Praulich I; Krings Rocha C; Kreuzer KA
Eur J Haematol; 2012 Jul; 89(1):53-62. PubMed ID: 22458420
[TBL] [Abstract][Full Text] [Related]
76. Clinical significance of FLT3-ITD/CEBPA mutations and minimal residual disease in cytogenetically normal acute myeloid leukemia after hematopoietic stem cell transplantation.
Wang H; Li XQ; Chu TT; Han SY; Qi JQ; Tang YQ; Qiu HY; Fu CC; Tang XW; Ruan CG; Wu DP; Han Y
J Cancer Res Clin Oncol; 2021 Sep; 147(9):2659-2670. PubMed ID: 33550446
[TBL] [Abstract][Full Text] [Related]
77. Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia.
Schlenk RF; Döhner K; Krauter J; Fröhling S; Corbacioglu A; Bullinger L; Habdank M; Späth D; Morgan M; Benner A; Schlegelberger B; Heil G; Ganser A; Döhner H;
N Engl J Med; 2008 May; 358(18):1909-18. PubMed ID: 18450602
[TBL] [Abstract][Full Text] [Related]
78. Beneficial tyrosine kinase inhibitor therapy in a patient with relapsed BCR-ABL1-like acute lymphoblastic leukemia with CCDC88C-PDGFRB fusion.
Oya S; Morishige S; Ozawa H; Sasaki K; Semba Y; Yamasaki Y; Nakamura T; Aoyama K; Seki R; Mouri F; Osaki K; Miyamoto T; Maeda T; Nagafuji K
Int J Hematol; 2021 Feb; 113(2):285-289. PubMed ID: 32951102
[TBL] [Abstract][Full Text] [Related]
79. Hematopoietic transplantation for acute myeloid leukemia with internal tandem duplication of FLT3 gene (FLT3/ITD).
Brunet S; Martino R; Sierra J
Curr Opin Oncol; 2013 Mar; 25(2):195-204. PubMed ID: 23385863
[TBL] [Abstract][Full Text] [Related]
80. Presence of FLT3 mutations does not impair stem cell mobilization and feasibility of autologous peripheral blood stem cell transplantation in acute myeloid leukemia.
Ferrara F; Palmieri S; Pollio F; Lo Pardo C; Graziano D; Celentano M; D'Amico MR; Vicari L; Izzo B; Pane F
Biol Blood Marrow Transplant; 2006 Sep; 12(9):981-6. PubMed ID: 16920565
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
